The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria

SIMPLE SUMMARY: The introduction of immune checkpoint inhibitors has represented a milestone in cancer treatment. Despite PD-L1 expression being the standard biomarker used before the start of therapy, there is still a strict need to identify complementary non-invasive biomarkers in order to better...

Descripción completa

Detalles Bibliográficos
Autores principales: Castello, Angelo, Castellani, Massimo, Florimonte, Luigia, Urso, Luca, Mansi, Luigi, Lopci, Egesta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948743/
https://www.ncbi.nlm.nih.gov/pubmed/35330068
http://dx.doi.org/10.3390/jcm11061740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948743/
https://www.ncbi.nlm.nih.gov/pubmed/35330068
http://dx.doi.org/10.3390/jcm11061740

Ejemplares similares